Vixotrigine

Vixotrigine
Clinical data
Other namesRaxatrigine; CNV1014802; GSK-1014802; BIIB 074
Routes of
administration		By mouth
ATC code
  • None
Identifiers
IUPAC name
  • (2S,5R)-5-[4-[(2-fluorophenyl)methoxy]phenyl]pyrrolidine-2-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC18H19FN2O2
Molar mass314.360 g·mol−1
3D model (JSmol)
SMILES
  • C1CC(NC1C2=CC=C(C=C2)OCC3=CC=CC=C3F)C(=O)N
InChI
  • InChI=1S/C18H19FN2O2/c19-15-4-2-1-3-13(15)11-23-14-7-5-12(6-8-14)16-9-10-17(21-16)18(20)22/h1-8,16-17,21H,9-11H2,(H2,20,22)/t16-,17+/m1/s1
  • Key:JESCETIFNOFKEU-SJORKVTESA-N

Vixotrigine (INN, USAN), formerly known as raxatrigine (INN, USAN), is an analgesic which is under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).[1][2][3] Vixotrigine was originally claimed to be a selective central Nav1.3 blocker, but was subsequently redefined as a selective peripheral Nav1.7 blocker. Following this, vixotrigine was redefined once again, as a non-selective voltage-gated sodium channel blocker. As of January 2018, it is in phase III clinical trials for trigeminal neuralgia and is in phase II clinical studies for erythromelalgia and neuropathic pain.[4] It was previously under investigation for the treatment of bipolar disorder, but development for this indication was discontinued.[4]

See also

References

  1. ↑ "CNV1014802". Convergence Pharmaceuticals.
  2. ↑ McMahon S, Koltzenburg M, Tracey I, Turk DC (1 March 2013). Wall & Melzack's Textbook of Pain: Expert Consult - Online. Elsevier Health Sciences. p. 508. ISBN 978-0-7020-5374-0.
  3. ↑ Bagal SK, Chapman ML, Marron BE, Prime R, Storer RI, Swain NA (August 2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–9. doi:10.1016/j.bmcl.2014.06.038. PMID 25060923.
  4. 1 2 "Vixotrigine - Biogen". Adis Insight. Springer Nature Switzerland AG.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.